Skip to content
Open access

Longitudinal Changes in Inflammation-Related Methylation Risk Score for C-Reactive Protein Among People with HIV

Aug 2026 · Epigenomes · Vol 10, pp. 54 · 0 citations · 56 references
Medicine

TL;DR

The observed decline in MRSCRP following ART initiation may reflect changes in inflammatory status among PWH, and highlights the potential of MRSCRP as a marker of inflammation-related changes and comorbidity risk in PWH.

Abstract

Background/Objectives: Human immunodeficiency virus (HIV) infection is characterized by chronic systemic inflammation. Antiretroviral therapy (ART) can reduce persistent inflammation, as measured by C-reactive protein (CRP). The CRP methylation risk score (MRSCRP) acts as proxy for plasma CRP, but longitudinal changes in this score for people with HIV (PWH) before and after initiating ART have not been described. Methods: We evaluated a previously published MRSCRP in the Emory Twin Study (N = 352), testing its correlation with plasma CRP and CRP-responsive biomarkers, as well as associations with cardiometabolic traits using generalized estimating equations (GEEs). We then applied MRSCRP in the HIV AIDS Drug Resistance Surveillance Study (ADReSS) cohort (N = 440) to assess longitudinal changes before and after ART, using paired t-tests and linear mixed-effects models. Results: MRSCRP showed moderate correlation with CRP (r = 0.38) and other inflammatory biomarkers (r = 0.25–0.34). MRSCRP was associated with hypertension, type 2 diabetes, coronary artery disease, and obesity, and remained independently associated with obesity (odds ratio = 1.49) after adjusting for measured CRP. Z-score-standardized MRSCRP decreased by 0.254 standard deviation units between baseline and follow-up among PWH receiving ART, confirmed by linear mixed-effects models. Conclusions: MRSCRP showed associations with chronic inflammation and cardiometabolic diseases. The observed decline in MRSCRP following ART initiation may reflect changes in inflammatory status among PWH. These findings highlight the potential of MRSCRP as a marker of inflammation-related changes and comorbidity risk in PWH.

Read PDF

Similar papers

Open access Sep 2026

Beyond traditional criteria: CRP and fibrinogen as biomarkers of metabolic syndrome in ART-treated people living with HIV and their association with HIF-1α rs11549465

Metabolic syndrome (MS) is highly prevalent among people living with HIV (PLWH) receiving antiretroviral therapy (ART) and is driven by persistent low-grade inflammation. Hypoxia-inducible factor 1 alpha (HIF-1α) polymorphisms may influence inflammatory pathways underlying MS. This study investigated the association of...

Nemanja Đorđević, J. Ranin, I. Gmizić et al. · 0 citations
Open access Oct 2026

Prognostic impact of high-sensitivity C-reactive protein trajectories and sustained residual inflammation for prediction of cardiovascular outcomes

Traditional risk factors for atherosclerotic cardiovascular disease (ASCVD) fail to fully reflect the residual risk, driven by chronic low-grade inflammation, observed in many. Generally, high-sensitivity C-reactive protein (hsCRP) concentrations remain stable, but some individuals may experience increases. More...

F. Kahles, M. Reugels, K. Schneider et al. · 0 citations
Open access Sep 2026

Inflammatory protein signatures as predictors of insulin resistance and cognitive function: a one-year longitudinal study in the mPRIME cohort

Background Large-scale studies have demonstrated a temporal relationship between insulin resistance (IR) and peripheral inflammation, with emerging evidence also suggesting a link to cognitive decline. However, most of the existing research has focused on individual inflammatory proteins, while the role of inflammatory...

C. Schiweck, Judith R. Gruber, J. Bralten et al. · 0 citations
Open access Oct 2026

Neutrophil-to-lymphocyte ratio enhances mortality prediction beyond c-reactive protein in metabolic syndrome: a multi-cohort study

Systemic inflammation is a key driver of cardiovascular risk in metabolic syndrome (MetS). Although C-reactive protein (CRP) is widely used, its prognostic value may be enhanced by cellular immune markers such as the neutrophil-to-lymphocyte ratio (NLR), which integrates innate and adaptive inflammatory pathways....

J. Yang, M. Li, Z. Zhang et al. · 0 citations
Open access Oct 2026

C-reactive protein–triglyceride-glucose index and diabetic vascular complications risk among patients with diabetes: a national cohort study

Abstract Introduction The C-reactive protein–triglyceride-glucose index (CTI) has emerged as an innovative biomarker for insulin resistance and inflammatory processes. Nevertheless, the association between CTI and diabetic vascular complications (DVCs) and its subtypes in individuals with diabetes remains unclear. Meth...

Shi-Kai Xiong, Hao Wang, Bin Wang et al. · 0 citations
Open access Oct 2026

Longitudinal high-sensitivity C-reactive protein assessment predicts cardiovascular risk in apparently healthy individuals

High-sensitivity C-reactive protein (hsCRP) is the guideline-recommended biomarker for assessment of residual inflammatory risk in atherosclerotic cardiovascular disease (ASCVD). Clinical adoption remains limited, especially in individuals without established ASCVD. This study used longitudinal measurements to ev...

B. Kurt, M. Reugels, K. Schneider et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.